Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30271733 | 1.00 | TRPV4 (0.47) | TRPV4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL531071 | 0.84 | APP (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16955070 | 0.81 | TRPV4 (0.52) | TRPV4SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL6100359 | 0.80 | APP (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3978580 | 0.80 | APP (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23011826 | 0.80 | APP (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL957890 | 0.80 | ADRB2 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16956706 | 0.80 | APP (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL960516 | 0.80 | ADRB2 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL31611813 | 0.80 | APP (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459927-B2 | Plasma kallikrein inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4210694-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-12428421-B2 | Pyrimidinones as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-30 | — | — | US | disclosed |
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-11 | — | — | US | disclosed |
| EP-4477220-A2 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-12-18 | — | — | EP | disclosed |
| EP-4031547-B1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20230416227-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-12-28 | — | — | US | disclosed |
| US-20230391773-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-07 | — | — | US | disclosed |
| CN-116987080-A | Macrocyclic compounds with heterocyclic P2' groups as factor XIA inhibitors | 百时美施贵宝公司 | 2023-11-03 | — | — | CN | disclosed |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| WO-2015116882-A1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-06 | — | — | WO | disclosed |
| CN-1867554-B | Piperazine with ortho-substituted phenyl and its use as GLYT1 inhibitors | HOFFMANN LA ROCHE | 2011-07-06 | — | — | CN | disclosed |
| US-7605163-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | JOLIDON SYNESE | 2008-05-22 | — | — | US | disclosed |
| US-7319099-B2 | Such as 1-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl benzoyl)-piperazin-1-yl]-phenyl}-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| EP-1656361-B1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-02 | — | — | EP | disclosed |
| CN-1867554-A | Piperazine with ortho-substituted phenyl and its use as GLYT1 inhibitors | HOFFMANN LA ROCHE (CH) | 2006-11-22 | — | — | CN | disclosed |
| EP-1656361-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005014563-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209241-A1 | Benzoyl-piperazine derivatives | SLC1A2, SLC18A2, SLC6A7 | TRPV4 480/4885PSEN1 100/4885PSEN2 115/4885 |
| US-20230416227-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, KLK5 | TRPV4 1619/4885PSEN1 2752/4885PSEN2 3156/4885 |
| US-12428421-B2 | Pyrimidinones as factor XIA inhibitors | TFPI, TFPI2, F2 | TRPV4 3603/4885PSEN1 392/4885PSEN2 421/4885 |
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | TRPV4 3988/4885PSEN1 3279/4885PSEN2 3537/4885 |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | TRPV4 3988/4885PSEN1 3279/4885PSEN2 3537/4885 |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | SLC1A2, SLC18A2, SLC6A7 | TRPV4 480/4885PSEN1 100/4885PSEN2 115/4885 |
| US-12459927-B2 | Plasma kallikrein inhibitors | KLKB1, SERPINE1, KLK5 | TRPV4 1619/4885PSEN1 2752/4885PSEN2 3156/4885 |
| US-20230391773-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | KLKB1, KLK1, KLK5 | TRPV4 3988/4885PSEN1 3279/4885PSEN2 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.